Lymerix withdrawal update
FDA will update vaccines advisory committee on GlaxoSmithKline's Lymerix during the afternoon of May 21. The company withdrew the lyme disease vaccine Feb. 25, citing low demand. The committee had previously reviewed reports of safety problems with the vaccine (11"The Pink Sheet" March 4, p. 23). The meeting will be held at the Hilton in Silver Spring, Md., at 8:30 a.m...
You may also be interested in...
GlaxoSmithKline has ceased production of Lymerix and will not be selling its remaining inventory of the Lyme disease vaccine
A senior Pfizer executive talks about the high regulatory expectations for public disclosure of clinical trial data for Comirnaty, the COVID-19 vaccine it developed in partnership with BioNTech. There were also concerns about re-identification of trial participants as many subjects took to social media to share their experiences with the Comirnaty study.
Sen. Patty Murray said she doesn’t want more uncertainty about user fees during the COVID-19 pandemic and will move to get all the user fees renewed before they expire in September.